Corrigendum: Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer

Hui-Wen Yang; Yan Lan; An Li; Han Wu; Zi-Wei Song; Ai-Ling Wan; Yue Wang; Shi-Bao Li; Shuai Ji; Zhong-Cheng Wang; Xin-Yu Wu; Ting Lan

doi:10.3389/fphar.2024.1447095

Corrigendum: Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer

Front Pharmacol. 2024 Nov 14:15:1447095. doi: 10.3389/fphar.2024.1447095. eCollection 2024.

Authors

Hui-Wen Yang^#^{1

2}, Yan Lan^#¹, An Li^{1

2}, Han Wu^{1

2}, Zi-Wei Song^{1

2

3}, Ai-Ling Wan^{1

2}, Yue Wang^{1

2}, Shi-Bao Li^{1

2

3}, Shuai Ji⁴, Zhong-Cheng Wang⁵, Xin-Yu Wu⁶, Ting Lan^{1

2}

Affiliations

¹ Xuzhou Key Laboratory of Laboratory Diagnostics, Xuzhou Medical University, Xuzhou, Jiangsu, China.
² School of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
³ Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
⁴ School of Pharmacology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
⁵ Department of Pathophysiology, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China.
⁶ Department of Laboratory Medicine, Affiliated Xuzhou Maternity and Child Health Care Hospital of Xuzhou Medical University, Xuzhou, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fphar.2023.1288883.].

Keywords: PI3K/AKT; TGF-β; TGF-β/Smad; epithelial-to-mesenchymal transition; myricetin; ovarian cancer.

Publication types

Published Erratum